Industry Distribution:

• Biotechnology: approx. 70%
• Pharmaceuticals: approx. 20%
• Healthcare services: approx. 10%

TOP 3 Markets:

1. USA: approx. 60%
2. Europe: approx. 25%
3. Asia-Pacific: approx. 10%

The iShares Biotechnology ETF (IBB) mainly invests in companies from the biotechnology sector, which make up the largest share of the portfolio. Pharmaceutical companies and healthcare service providers complement the portfolio to ensure broader coverage of the healthcare sector.

The USA is the largest market for the ETF, attributed to the high concentration of biotechnology and pharmaceutical companies in this country. Europe and the Asia-Pacific region follow, with these regions also being significant centers for biotechnological innovation and development.

iShares Trust - iShares Biotechnology ETF (NasdaqGM:IBB)

iShares Trust - iShares Biotechnology ETF (IBB) is not a company that produces physical products. It is an exchange-traded fund (ETF) that invests in a variety of companies in the biotechnology sector.

The ETF itself does not produce products, but holds shares in various biotechnology companies that operate worldwide. These companies may have production facilities at different locations, depending on their individual business activities and global presence.

Growth Strategy: Diversification and Innovation in the Biotechnology Sector

The iShares Biotechnology ETF (IBB) pursues a strategy focused on diversification and innovation in the biotechnology sector. The ETF invests in a broad range of biotechnology companies to spread risk and benefit from various growth opportunities within the industry.

A key component of the strategy is the focus on companies engaged in the development of new drugs and therapies. This includes both established firms and emerging biotech companies that are potentially developing groundbreaking technologies.

Additionally, the ETF integrates companies operating in the fields of genomics, personalized medicine, and biopharmaceutical innovations. These areas are considered particularly high-growth and offer long-term potential for returns.

By continuously adjusting the portfolio composition to the latest scientific and technological advancements, the ETF aims to benefit from the dynamic developments in the biotechnology sector.

Commodities/Materials: No direct imports

The iShares Biotechnology ETF (IBB) is an exchange-traded fund that invests in biotechnology companies. As an ETF, it does not directly import commodities or materials. Instead, it invests in stocks of companies operating in the biotechnology sector.

However, these companies may import commodities and materials necessary for research, development, and production of biotechnological products. Typical materials could include chemical compounds, laboratory equipment, and biological samples.

The countries of origin for these materials vary depending on the specific requirements of the companies and global supply chains. Common import countries for biotechnological materials are the USA, Germany, China, and Japan, as these countries have strong biotechnological and pharmaceutical industries.

Competitive Advantage: Moderate

The iShares Biotechnology ETF (IBB) is an exchange-traded fund that invests in a variety of biotechnology companies. The competitive advantage of the ETF itself is moderate, as it represents an attractive investment option for investors looking to benefit from growth opportunities in the biotechnology sector due to its broad diversification and focus on this sector.

The ETF provides access to a portfolio of leading biotechnology companies, reducing the risk of individual company failures while increasing the chances of above-average returns. However, the competitive advantage of the ETF is limited by the high volatility and regulatory risks in the biotechnology sector.

In addition, the IBB competes with other biotechnology ETFs and investment funds that pursue similar investment strategies. Nevertheless, due to its size, liquidity, and the reputation of iShares, the IBB remains a preferred choice for many investors.

Institutional Investor Share: approx. 80% (estimated, based on typical ETF data)

Insider Buys/Sells: Not applicable to ETFs

The iShares Biotechnology ETF (IBB) is an exchange-traded fund that typically has a high proportion of institutional investors. This is because ETFs are often used by institutional investors such as pension funds, mutual funds, and hedge funds to achieve diversified exposure to specific sectors.

Insider buys or sells are not relevant for ETFs, as ETFs do not represent individual company shares but rather track a basket of stocks. Therefore, there are no "insiders" in the traditional sense as with individual companies.

Market share of iShares Biotechnology ETF (IBB): Approximately 15% (2025)

Top competitors and their market shares:

1. SPDR S&P Biotech ETF (XBI): 12%
2. First Trust NYSE Arca Biotechnology Index Fund (FBT): 10%
3. VanEck Vectors Biotech ETF (BBH): 8%
4. Invesco Dynamic Biotechnology & Genome ETF (PBE): 7%
5. ARK Genomic Revolution ETF (ARKG): 6%

The iShares Biotechnology ETF (IBB) holds a significant market share in the biotechnology ETF sector and is one of the leading funds in this industry. Its moat stems from broad diversification and strong brand recognition supported by the iShares family. This provides investors with a certain level of stability and confidence in the fund's long-term performance.

Compared to its competitors, IBB benefits from a larger market capitalization and an established network. However, some competing ETFs, such as the SPDR S&P Biotech ETF (XBI), offer different weighting and strategies that may be more attractive to certain investors. These differences in strategy can be seen as moats for the respective ETFs, as they provide varying risk profiles and return opportunities.

Overall, IBB has a solid moat due to its size and diversification, but the competition also offers strong alternatives that can be attractive depending on market conditions and investor preferences.

Fund assets: $10.5 billion (2025)

Number of holdings: 270 (2025)

Average annual return (5 years): 8.2% (until 2025)

The iShares Biotechnology ETF (IBB) provides investors with access to a broad range of companies in the biotechnology sector. The fund has a substantial asset base of $10.5 billion and invests in 270 different companies, offering good diversification within the sector.

Over the past five years, the ETF has achieved an average annual return of 8.2%. This performance demonstrates solid growth, supported by the innovation and growth potential of the biotechnology industry.

Biotechnology remains a sector with high growth potential, particularly due to advances in genomics research, personalized medicine, and new therapeutic approaches. However, investors should also consider the sector's volatility, influenced by regulatory risks and technological uncertainties.

Overall, the iShares Biotechnology ETF could be a good investment for investors interested in long-term growth in the biotechnology sector and willing to bear the associated risks.

Dividend yield: 0.3% (estimated for 2025)

The iShares Biotechnology ETF (IBB) usually pays a dividend, but the dividend yield is relatively low compared to other ETFs. This is because the ETF mainly invests in biotechnology companies that often reinvest their profits in research and development instead of paying out high dividends.

While the payout is regular, it is not very high and can vary from year to year depending on the earnings of the companies included in the ETF. Therefore, investors should focus more on the growth potential of the biotechnology industry rather than on the dividend yield.